Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.

Biotechnology

Manufacturing

Oxford Biomedica Solutions

Tim Kelly

Ryan Dickerson

Melissa P.

Kelly Quesada

Volker Glidden

Stephen Boyd

Marissa Stanvick

Diane Golebiowski

David Hamilton

Lori Karpes

Amy P.

Patricia Daggett

The Research and Development team at Oxford Biomedica Solutions is responsible for advancing the innovation and efficacy of AAV and lentiviral vector manufacturing for cell and gene therapies. This team conducts cutting-edge research, analytical development, and process optimization to support the creation of robust therapeutic solutions. Comprising scientists and research associates, they focus on designing and improving vector engineering, downstream processing, and analytical techniques to accelerate the delivery of life-changing therapies to patients worldwide.

Research and Development

Director Team

Quality Control and Assurance Team

Research and Development

About

Team members

Other teams at Oxford Biomedica Solutions

Director Team

Quality Control and Assurance Team